Skip to main content
. 2018 Mar 26;128(5):1737–1751. doi: 10.1172/JCI93198

Figure 7. JAM3 supports the growth of human acute myeloid LICs.

Figure 7

(A) Representative flow cytometric analysis of JAM3 expression on the immunophenotypic Lin–CD34+CD38–CD90–CD45RA+ LICs (LMPP cells) and CD34–CD38– differentiated human AML cells (AML#7 in Supplemental Table 2). (B) Quantification of the MFIs for JAM3 expression on LMPP cells or CD34–CD38– differentiated leukemia cells in A (AML#2, #5, #6, #8 in Supplemental Table 2; n = 5; *P < 0.05, Student’s t test). (C) Quantification of the relative frequency of JAM3+ cells in LMPP or CD34–CD38– differentiated leukemia cells in A (n = 5; *P < 0.05, Student’s t test). (D–H) Cell numbers of 5 patient AML samples were counted at the indicated days after knockdown of JAM3 by sh1188 or scrambled shRNA (AML#1–AML#5 in Supplemental Table 2; n = 3; **P < 0.01, ***P < 0.001, 2-way ANOVA followed by Bonferroni’s post-test). Experiments were conducted 3–5 times for validation.